Almac Launch Biomarkers for Biopharma

CRAIGAVON, Northern Ireland, August 2, 2010 - Almac today announced the launch of Biomarkers for biopharma
(www.almacgroup.com/biomarkersforbiopharma/); a range of solutions
specifically designed to meet the needs of the biopharma industry.

Almac's solutions are to support biopharma companies in adopting
biomarker strategies to enable them to better understand their drug, improve
their drug's success rate, improve the drug's value and ultimately maximise
their drug's potential.

The use of biomarkers can add substantial value to a compound in
development and the ability to identify those patients most likely to respond
to a therapy greatly increases the chances of success and the licensing
potential of the drug.

Biomarkers for biopharma solutions include pharmacodynamic solutions,
patient selection markers, assay development and bioinformatics /
biostatistics consultancy.

President and Managing Director of Almac's Diagnostics (
www.almacgroup.com/diagnostics/) division, Professor Paul Harkin said:

"With Biomarkers for biopharma, we have combined a range of key solutions
which are ideally suited to growing biopharma companies. For these companies,
it is of critical importance that they maximise the potential success of the
drugs in their pipeline and the incorporation of a biomarker strategy enables
them to do this."

Almac support and guide companies, enabling biomarker strategies that
will maximise their drugs and business's potential.

For further information on Biomarkers for biopharma visit
www.almacgroup.com/biomarkersforbiopharma

Notes to Editors

About Almac

The Almac Group comprises five closely integrated divisions offering a
broad range of services from R&D, biomarker discovery and development, API
manufacture, formulation development, clinical trial supply and technology
(IVRS & Web), to commercial-scale manufacture. Almac provides services to
more than 600 companies, including all the world leaders in the
pharmaceutical and biotech sectors. The company employs over 2,600
individuals and is headquartered in Craigavon, Northern Ireland. US
operations are based in Pennsylvania, North Carolina and California.
Construction of the company's new $120m North American Headquarters started
in July 2008 and will be completed 2010.

Almac's Diagnostics division is a personalised medicine company focused
on the discovery and development of biomarkers. They utilise their
proprietary technology and extensive experience and expertise to offer
solutions to biotech and Pharma partners. Almac focus on providing a range of
services including exploratory biomarker discovery studies, verification
studies for existing markers, assay development and biomarker validation.

For more information about the Almac Group, please visit
www.almacgroup.com or e-mail info@almacgroup.com.

    Michael Sloan
    Almac Diagnostics
    michael.sloan@almacgroup.com
    Tel: +44-28-38337575

    Tristan Jervis
    De Facto Communications
    T.Jervis@Defacto.com
    Tel: +44-2078-613019

Michael Sloan, Almac Diagnostics, michael.sloan at almacgroup.com, Tel: +44-28-38337575; Tristan Jervis, De Facto Communications, T.Jervis at Defacto.com, Tel: +44-2078-613019